Raheem Omer A, Natale Caleb, Dick Brian, Reddy Amit G, Yousif Ayad, Khera Mohit, Baum Neil
Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.
Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.
Sex Med Rev. 2021 Jan;9(1):123-132. doi: 10.1016/j.sxmr.2020.03.005. Epub 2020 Jul 4.
Although available treatments for erectile dysfunction (ED) have expanded, there has been a concomitant shift in the treatment paradigm. Newer treatment options focus on disease modification and improving overall erectile function.
The objective of this study is to review the evidence of 3 promising novel ED treatments.
A thorough review of the literature was divided into sections corresponding to low-intensity extracorporeal shockwave therapy (Li-ESWT), stem cell therapy (SCT), and platelet-rich plasma (PRP). Search terms included "erectile dysfunction" or "ED" plus "extracorporeal shockwave therapy", "stem cell therapy" or "platelet rich plasma". International Index of Erectile Function (IIEF) scores were the primary outcome measure. Secondary outcome measures included peak systolic velocity and intracorporeal pressure.
Li-ESWT section includes 1 randomized controlled study, 2 prospective studies, 1 animal study, and 2 meta-analyses. IIEF score improvement was 3.54 (range 1.99-6.40). Authors concluded statistically significant short-term effect and improvement in erectile function (EF) with Li-ESWT. SCT section included 4 case series and 1 open-label study. Intraperitoneal, venous, and cavernosal SCT injections improved EF in animal models. 3 studies (n = 6-8) demonstrated 83-100% and 29-50% of patients regained erection and penetration ability, respectively. 2 studies (n = 12-16) found that all patients improved IIEF scores after SCT. Literature review for PRP yielded 3 animal, 1 retrospective, and 1 prospective study. Animal studies have shown that rats sustaining crush cavernosal injuries treated with PRP significantly improved EF and preservation of cavernous nerve axons. One retrospective analysis on humans showed mean improvement by 4.14 in IIEF scores. One prospective study on humans (n = 75) demonstrated improved peak systolic velocity (P = .005) and IIEF scores (P = .046) with PRP therapy.
This review reveals limited published evidence on current novel ED treatment options. Further research on Li-ESWT, SCT, and PRP therapy is necessary to elucidate the role of these therapies in ED treatment regimens. Raheem OA, Natale C, Dick B, et al. Novel Treatments of Erectile Dysfunction: Review of the Current Literature. Sex Med Rev 2021;9:123-132.
虽然勃起功能障碍(ED)的现有治疗方法有所增加,但治疗模式也随之发生了转变。更新的治疗选择侧重于疾病改善和提高整体勃起功能。
本研究的目的是回顾3种有前景的新型ED治疗方法的证据。
对文献进行全面回顾,分为与低强度体外冲击波疗法(Li-ESWT)、干细胞疗法(SCT)和富血小板血浆(PRP)相对应的章节。检索词包括“勃起功能障碍”或“ED”加上“体外冲击波疗法”、“干细胞疗法”或“富血小板血浆”。国际勃起功能指数(IIEF)评分是主要结局指标。次要结局指标包括收缩期峰值流速和海绵体内压。
Li-ESWT章节包括1项随机对照研究、2项前瞻性研究、1项动物研究和2项荟萃分析。IIEF评分改善为3.54(范围1.99 - 6.40)。作者得出结论,Li-ESWT在短期内对勃起功能(EF)有统计学意义的改善。SCT章节包括4个病例系列和1项开放标签研究。腹腔内、静脉内和海绵体内SCT注射在动物模型中改善了EF。3项研究(n = 6 - 8)表明,分别有83% - 100%和29% - 50%的患者恢复了勃起和插入能力。2项研究(n = 12 - 16)发现,所有患者在SCT后IIEF评分均有所改善。PRP的文献综述产生了3项动物研究、1项回顾性研究和1项前瞻性研究。动物研究表明,用PRP治疗遭受挤压性海绵体损伤的大鼠可显著改善EF并保留海绵体神经轴突。一项对人类的回顾性分析显示IIEF评分平均提高4.14。一项对人类的前瞻性研究(n = 75)表明,PRP治疗可改善收缩期峰值流速(P = .005)和IIEF评分(P = .046)。
本综述揭示了关于当前新型ED治疗选择的已发表证据有限。有必要对Li-ESWT、SCT和PRP疗法进行进一步研究,以阐明这些疗法在ED治疗方案中的作用。拉希姆·奥阿、纳塔莱·C、迪克·B等。勃起功能障碍的新型治疗方法:当前文献综述。性医学评论2021;9:123 - 132。